We recently identified 1α, 25-dihydroxy-3-epi-vitamin D
3 [1 α, 25(OH)
2-3-epi-D
3] as a metabolite of 1 α, 25-dihydroxyvitamin D
3 [1α, 25(OH)
2D
3] produced in rat osteosarcoma cells (UMR 106). We now report the isolation of 24
R, 25-dihydroxy-3-epi-vitamin D
3 [24
R, 25 (OH)
2-3-epi-D
3] as a metabolite of 24
R, 25-dihydroxyvitamin D
3 [24
R, 25(OH)
2D
3] by high-performance liquid chromatography (HPLC) with chiral column and its structure assignment by proton nuclear magnetic resonance (
1H-NMR) and liquid chromatography-mass spectrometry (LC-MS) analysis. We also demonstrated the production of 24
R, 25(OH)
2-3-epi-D
3 in two other cell lines [human colon carcinoma cells (Caco-2) and porcine kidney cells (LLC-PK
1)] which were previously shown to convert 1 α, 25(OH)
2D
3 into 1 α, 25 (OH)
2-3-epi-D
3. It can be seen that the production of 24
R, 25 (OH)
2-3-epi-D
3 from 24
R, 25(OH)
2D
3 is lower than that of 1 α, 25 (OH)
2-3-epi-D
3 from 1α, 25(OH)
2D
3 in all the cells studied. 24
R, 25(OH)
2-3-epi-D
3 was found to be inactive in terms of its ability to bind to the vitamin D receptor (UDR), in inhibiting proliferation and in inducing differentiation of human promyelocytic leukemia cells (HL-60). Thus, our study indicates that the C-3 epimerization pathway is common to both lα, 25(OH)
2D
3 and 24
R, 25(OH)
2D
3 and may play an important role in modulating the concentration and the biological activity of these two major vitamin D
3 metabolites in target tissues.
View full abstract